Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • PharmaTutor
    23 March 2010

    FDA Temporarily Suspends Use of Rotarix Vaccine

    March 22, 2010 — The US Food and Drug Administration (FDA) announced today viral contamination of GlaxoSmithKline's Rotarix vaccine. The agency is recommending that doctors stop using the vaccine until further investigations are complete.

    An independent academic research team testing the product recently identified porcine circovirus 1 in the vaccine and notified regulators.

  • 20 March 2010
    High-Dose Simvastatin Associated With Increased Risk for Myopathy

     March 19, 2010 — Simvastatin (Zocor, Merck/Schering-Plough Pharmaceuticals), used at the highest approved dose of 80 mg, is associated with an increased risk for myopathy, including rhabdomyolysis, according to the US Food and Drug Administration (FDA).

  • 20 March 2010
    Local players to continue domination in anti-fungal drug market in India: F&S

     With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFIs) is expected to increase steadily over the next five years, says a new analysis from Frost & Sullivan entitled Systemic Fungal Infection Therapeutics Market – India.

  • 20 March 2010
    Drugs of Crores Rs. seized by Tamil nadu drug authorities

    In a series of raids conducted in several places of the city and in various parts of the state during the last 10 days, the state drug authorities have detected several illegal activities of the pharma traders in which expired and label tampered drugs worth lakhs of rupees were seized from shops of stockists and residences of unlicensed persons

  • 20 March 2010
    Intas Pharma to introduce world’s first Interferon Lozenges in tablet form for flu in India

    Following the recent license and supply agreement signed between Amarillo Biosciences Inc. (ABI), a US biotechnology firm, and Intas Pharmaceuticals, Intas will soon market world’s first Interferon Lozenges (tablet form) in India.

  • 19 March 2010
    IPA demands amendment of D&C Act, separate University for pharmacy in TN

     The Indian Pharmaceutical Association (IPA) has demanded to amend the Drugs & Cosmetics Act and Rules 1945 to make only the pharmacy graduates eligible to become expert staffs in the pharma manufacturing units. In the resolutions passed during the just concluded IPA Convention, the IPA also urged the government to expedite action to amend the Rules in such way that all regulatory positions in the country must be an exclusive area for experienced and qualified pharmacists.

    [adsense:336x280:8701650588]

  • 19 March 2010
    NIPER Ahmedabad to introduce PG diploma course for medical devices sector in July, 2010

     The National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, is all set to launch India's first dedicated course in medical devices segment from the new academic year starting from July, 2010. The institute is currently in talks with some of the major educational institutes conducting similar courses in the country for expert opinion and will finalise the curriculum soon, senior officials of the institute said.

  • 19 March 2010
    Bangalore India Bio expects wide biotech industry participation

     Technology Vision Group (TVG) has announced a collaboration with India-based MMActiv, ABLE and the Vision Group on Biotechnology to produce BioPartnering India (BPI) at Bangalore India Bio, India's largest biotechnology event, which is scheduled on June 2-4, 2010. These combined events offer delegates the opportunities for partnering in India.

  • 17 March 2010
    NEWS: Warfarin Genotyping Reduces Hospitalizations

    March 16, 2010 (Atlanta, Georgia) — Genotyping warfarin  patients resulted in a 30% reduction in all-cause hospitalizations and hospitalizations for bleeds/thromboemboli, a new study suggests.

  • 17 March 2010
    Duty of regulatory agencies must be to prevent harm from unsafe drugs, Kim Huynh-Ba.

    The primary duty of the regulatory bodies across the world is to prevent harm from unsafe drugs. In the United States, the law ensures that there shall be a written stability testing programme to assess the stability characteristics of drug products. Stability is the critical quality attribute of a drug product. Further it ensures the capacity of a drug substance, said Kim Huynh-Ba, Technical director of Pharmalytik, Newark in USA.

Subscribe to Pharma News